JOSEPH JANKOVIC to Dopamine Agents
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Dopamine Agents.
Connection Strength
1.088
-
Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna). 2020 05; 127(5):843-850.
Score: 0.668
-
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
Score: 0.167
-
Medical treatment of dystonia. Mov Disord. 2013 Jun 15; 28(7):1001-12.
Score: 0.106
-
Treatment of dystonia. Lancet Neurol. 2006 Oct; 5(10):864-72.
Score: 0.066
-
Dystonia. Nat Rev Dis Primers. 2018 09 20; 4(1):25.
Score: 0.038
-
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
Score: 0.022
-
Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000 Mar 10; 281(2-3):167-70.
Score: 0.011
-
Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999 Nov; 73(5):2218-21.
Score: 0.010